Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,762 across all filing types
Latest filing 2024-02-02 Regulatory Filings
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Audio recording
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchanges (BSE and NSE) regarding the audio recording of a conference call with analysts and investors about the financial results for the quarter and nine months ended 31st December 2023. It references a previous letter and provides a link to the audio recording on the company's website. The document does not contain the transcript itself, nor detailed financial data or analysis. It is essentially an announcement about the availability of the conference call recording. According to the classification rules, a document that announces or provides a link to a conference call recording without including the full transcript should be classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full call transcript (CT). The document length is short (1497 characters), supporting that it is an announcement rather than the full transcript.
2024-02-02 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the audio recording of a conference call with analysts and investors about the financial results for the quarter and nine months ended December 31, 2023. It references a previous letter and provides a link to the audio recording on the company's website. The document does not contain the transcript itself, nor detailed financial data or analysis. It is essentially an announcement about the availability of the conference call recording. Given the content and length (1497 characters), this fits the category of a Call Transcript (CT) announcement but not the transcript itself. However, since it is an announcement of the audio recording of the call, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement, because it does not contain the full transcript text. The document is not a full transcript, nor a financial report, nor a presentation. Therefore, the classification is RNS with high confidence.
2024-02-02 English
Date of payment of dividend
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements. It announces the approval by the Board of Directors of audited standalone financial results and unaudited consolidated financial results for the quarter and nine months ended December 31, 2023, along with audit and limited review reports. It also announces an interim dividend and changes in board membership. The document is relatively short (3044 characters) and serves as an announcement of financial results and board changes rather than containing the full financial statements or detailed analysis. It includes a press release and mentions that detailed results will be available on the company's website. Therefore, it is not a full Interim/Quarterly Report (IR) or Annual Report (10-K), but rather a Regulatory Filing (RNS) as it is an official regulatory announcement of financial results and board changes without the full report content.
2024-02-02 English
Dividend update
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements. It announces the Board's approval of audited standalone financial results and unaudited consolidated financial results for the quarter and nine months ended December 31, 2023, along with the audit and limited review reports. It also mentions the declaration of an interim dividend and changes in board membership. The document is relatively short (3044 characters) and primarily serves as an intimation or announcement of the financial results and related corporate actions rather than containing the full financial statements or detailed analysis itself. Therefore, it fits best as a Regulatory Filing (RNS) rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2024-02-02 English
Press Release
Regulatory Filings
2024-02-02 English
Date of payment of dividend
Regulatory Filings
2024-02-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.